GLP-1 Responses Are Heritable and Blunted in Acquired Obesity With High Liver Fat and Insulin Resistance
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
OBJECTIVE Impaired incretin response represents an early and uniform defect in type 2 diabetes, but the contributions of genes and the environment are poorly characterized. RESEARCH DESIGN AND METHODS We studied 35 monozygotic (MZ) and 75 dizygotic (DZ) twin pairs (discordant and concordant for obesity) to determine the heritability of glucagon-like peptide 1 (GLP-1) responses to an oral glucose tolerance test (OGTT) and the influence of acquired obesity to GLP-1, glucose-dependent insulinotropic peptide (GIP), and peptide YY (PYY) during OGTT or meal test. RESULTS The heritability of GLP-1 area under the curve was 67% (95% CI 45-80). Cotwins from weight-concordant MZ and DZ pairs and weight-discordant MZ pairs but concordant for liver fat content demonstrated similar glucose, insulin, and incretin profiles after the OGTT and meal tests. In contrast, higher insulin responses and blunted 60-min GLP-1 responses during the OGTT were observed in the heavier as compared with leaner MZ cotwins discordant for BMI, liver fat, and insulin sensitivity. Blunted GLP-1 response to OGTT was observed in heavier as compared with leaner DZ cotwins discordant for obesity and insulin sensitivity. CONCLUSIONS Whereas the GLP-1 response to the OGTT is heritable, an acquired unhealthy pattern of obesity characterized by liver fat accumulation and insulin resistance is closely related to impaired GLP-1 response in young adults.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a limited body of evidence supporting a modest reduction in gut GLP-1 release in people living with obesity, which may be partly heritable (14, 132‐134).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [132]
In the citing paper
“There is a limited body of evidence supporting a modest reduction in gut GLP-1 release in people living with obesity, which may be partly heritable (14, 132‐134).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [132]
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · cited 2×
“It must be noted that the DZ weight-discordant twin pairs did not undergo liver fat measurement but as a group they clearly represent the unhealthy obesity pattern based on significantly higher HOMA-IR and lower Matsuda indices.”
MethodIntroduction to Quantitative Genetics.
Edwards, A. W. F., & Falconer, D. S. (1982) · Biometrics · doi:10.2307/2529912 · Cited by 21,447
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621 · cited 1×
“HOMA-IR (14) and Matsuda index (15) were calculated using glucose and insulin measurements from the OGTT measurements.”
MethodMethodology for Genetic Studies of Twins and Families
Neale, M. C., & Cardon, L. R. (1992) · doi:10.1007/978-94-015-8018-2 · Cited by 4,005
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index
MAGIC, Speliotes, E. K., on behalf of Procardis Consortium, Willer, C. J., Berndt, S. I., Monda, K. L., Thorleifsson, G., Jackson, A. U., Allen, H. L., Lindgren, C. M., et al. (2010) · Nature Genetics · doi:10.1038/ng.686 · Cited by 2,912
Self-citationByrd, W. P. (1961) · Agronomy Journal · doi:10.2134/agronj1961.00021962005300010026x · Cited by 1,572
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 3×
“A severely reduced incretin response is a uniform finding in type 2 diabetes, in which the β-cell insulin secretion due to incretins may be reduced to < 20% from that of healthy subjects (2).”
BackgroundResultTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919 · cited 1×
“The plasma concentrations of GLP-1 were measured (17) against standards of synthetic GLP-1 7-36amide using antiserum code #89390, which is specific for the amidated C-terminus of GLP-1 and therefore does not react with GLP-1containing peptides from the pancreas.”
MethodSelf-citationVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884 · cited 1×
“The data in subjects with diabetes on GLP-1 and GIP plasma levels are conflicting with studies reporting especially reduced, unaltered and increased GIP concentrations after OGTT (2, 30-33).”
ResultSelf-citationDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869 · cited 1×
“The data in subjects with diabetes on GLP-1 and GIP plasma levels are conflicting with studies reporting especially reduced, unaltered and increased GIP concentrations after OGTT (2, 30-33).”
ResultSelf-citation
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“com meta-analysis of 22 clinical studies revealed no difference in glucosestimulated GLP-1 secretion between patients with type-2 diabetes and non-diabetic controls [263,264].”
BackgroundSelf-citationIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
“Regarding the secretion of GLP-1 in obesity, reduced increments in meal-related GLP-1 responses have been described with increasing body mass index, in particular in the presence of hepatic steatosis.(125) The incretin effect has been reported to be decreased in obesity,(123) even in the absence of impaired glucose to…”
BackgroundFærch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321
“Radioimmunological determinations of total plasma GLP-1 concentration [intact GLP-1 plus the metabolite GLP-1(9-36)amide] were performed as described previously (23–25).”
BackgroundMethodResultSelf-citationGlucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
Self-citationMetabolically healthy and unhealthy obese – the 2013 Stock Conference report
Samocha‐Bonet, D., Dixit, V. D., Kahn, C. R., Leibel, R. L., Lin, X., Nieuwdorp, M., Pietiläinen, K. H., Rabasa‐Lhoret, R., Roden, M., Scherer, P. E., et al. (2014) · Obesity Reviews · doi:10.1111/obr.12199 · Cited by 169
Self-citationMatikainen, N., Söderlund, S., Björnson, E., Pietiläinen, K., Hakkarainen, A., Lundbom, N., Taskinen, M., & Borén, J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13487 · Cited by 129
“Interestingly, impaired incretin effects have been observed in patients with NAFLD, both with and without diabetes.(18,19) Consequently, GLP-1 receptor agonists are increasingly recognized as potential agents for treating NAFLD in patients with and without diabetes.”
BackgroundSelf-citationGLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“In a study of 35 monozygotic and 75 dizygotic twin pairs (discordant and concordant for obesity), it was found that the heritability of the GLP-1 response was 67% 81 .”
Self-citationEnteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery
Holst, J. J. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.014 · Cited by 116
Self-citationDennis, J. M., Shields, B. M., Hill, A. V., Knight, B. A., McDonald, T. J., Rodgers, L. R., Weedon, M. N., Henley, W. E., Sattar, N., Holman, R. R., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1827 · Cited by 92
“also been shown that GLP-1 response is blunted in obese insulin-resistant patients with high liver fat and also blunted in patients with high fasting triglycerides (39,40); therefore, impaired GLP-1 secretion in obese insulin-resistant individuals represents a potential indirect mechanism that could also account for t…”
ResultJunker, A. E., Gluud, L., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12462 · Cited by 88
Self-citationWhat Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?
Kuhre, R. E., Deacon, C. F., Holst, J. J., & Petersen, N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.694284 · Cited by 78
“Collectively, therefore, these studies suggest that the diminished GLP-1 responses observed in individuals living with obesity (77, 78) are unlikely to be due to depleted stores.”
BackgroundResultSelf-citationShields, B. M., Dennis, J., Angwin, C. D., Warren, F. C., Henley, W., Farmer, A. A., Sattar, N. A., Holman, R. R., Jones, A. G., Pearson, E. R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02120-7 · Cited by 76
“…mechanisms include the impact of high insulin resistance on the action of a drug that acts predominantly through potentiating insulin secretion, impaired GLP-1 secretion in obesity or direct effects of lipotoxicity on GLP-1 receptor expression, which have been demonstrated in animal models 21–23 .”
FinnTwin16: A Longitudinal Study from Age 16 of a Population-Based Finnish Twin Cohort
Kaidesoja, M., Aaltonen, S., Bogl, L. H., Heikkila, K. V., Kaartinen, S., Kujala, U. M., Kärkkäinen, U., Masip, G., Mustelin, L., Palviainen, T., et al. (2019) · Twin Research and Human Genetics · doi:10.1017/thg.2019.106 · Cited by 69
“, 2014), hyperinsulinemia, blunted gut hormone (glucagon-like peptide-1) response to glucose and meals (Matikainen et al., 2013), as well as derangements in circulating lipoproteins (Kaye et al.”
BackgroundSelf-citationSonne, D. P., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0309 · Cited by 65
Self-citationGLP-1: A Mediator of the Beneficial Metabolic Effects of Bariatric Surgery?
Manning, S., Pucci, A., & Batterham, R. L. (2015) · Physiology · doi:10.1152/physiol.00027.2014 · Cited by 63
Huber, H., Schieren, A., Holst, J. J., & Simon, M.-C. (2024) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2024.01.007 · Cited by 62
“In twin pairs discordant and concordant for OW, an acquired unhealthy pattern of OW, characterized by liver fat accumulation and insulin resistance, was closely related to an impaired glucose-stimulated GLP-1 response [103].”
BackgroundSelf-citationChronic Exposure to TNFα Impairs Secretion of Glucagon-Like Peptide-1
Gagnon, J., Sauvé, M., Zhao, W., Stacey, H. M., Wiber, S. C., Bolz, S.-S., & Brubaker, P. L. (2015) · Endocrinology · doi:10.1210/en.2015-1361 · Cited by 53
Holst, J. J., Albrechtsen, N. J. W., Rosenkilde, M. M., & Deacon, C. F. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180013 · Cited by 54
Self-citationGenetic determinants of circulating GIP and GLP-1 concentrations
Almgren, P., Lindqvist, A., Krus, U., Hakaste, L., Ottosson-Laakso, E., Asplund, O., Sonestedt, E., Prasad, R. B., Laurila, E., Orho-Melander, M., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93306 · Cited by 53
“The heritability/familiality of incretin secretion during OGTT has previously been estimated to be in the 50%–75% range (31, 32), which is markedly higher than the heritability estimates obtained in this study.”
ResultSelf-citationGLP-1 and the Neurobiology of Eating Control: Recent Advances
Jones, L. A., & Brierley, D. I. (2025) · Endocrinology · doi:10.1210/endocr/bqae167 · Cited by 43
“There is a limited body of evidence supporting a modest reduction in gut GLP-1 release in people living with obesity, which may be partly heritable (14, 132–134).”
Therapies for inter-relating diabetes and obesity – GLP-1 and obesity
Iepsen, E. W., Torekov, S. S., & Holst, J. J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.965678 · Cited by 43
“However, a Finnish twin study estimated the heritability of GLP-1 response to an OGTT to be as much as 67% but also found that acquired obesity is closely related to impaired GLP-1 response [49] suggesting that impaired GLP-1 function is strongly influenced by susceptibility genes as well as lifestyle factors.”
BackgroundSelf-citationRegulation of glucose metabolism in nondiabetic, metabolically obese normal-weight Asians
Ding, C., Chan, Z., Chooi, Y. C., Choo, J., Sadananthan, S. A., Chang, A., Sasikala, S., Michael, N., Velan, S. S., & Magkos, F. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00382.2017 · Cited by 45
“GLP-1 secretion is modulated by many factors, including dietary nutrients (21) and physical activity habits (1) but also genetics/ heritability (2, 35).”
BackgroundObesity and Bipolar Disorder: Synergistic Neurotoxic Effects?
Liu, C. S., Carvalho, A. F., Mansur, R. B., & McIntyre, R. S. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0067-7 · Cited by 42
New insight of obesity-associated NAFLD: Dysregulated “crosstalk” between multi-organ and the liver?
Wang, Y., Wu, L.-L., Qi, X.-Y., Wang, Y.-Y., Liao, Z., Liu, J., & Xiao, X. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2021.12.013 · Cited by 40
“Congruously, GLP-1 responses are also blunted in patients with obesity-induced NAFLD.(93) Importantly, growing evidence indicates a direct protective effect of GLP-1 on the liver, which can be summarized as follows.”
BackgroundRameshrad, M., Razavi, B. M., Lalau, J., Broe, M. E. D., & Hosseinzadeh, H. (2020) · PubMed Central · doi:10.22038/ijbms.2020.41638.9832 · Cited by 41
“Restoring this damage results in a potential therapy for these diseases (52, 54, 55).”
BackgroundLee, Y. S., Riopel, M., Cabrales, P., & Bandyopadhyay, G. K. (2019) · Science Advances · doi:10.1126/sciadv.aaw4176 · Cited by 33
“Increased adiposity and insulin resistance are associated with this defect ( 23 ), but the underlying mechanisms are poorly understood.”
Older Subjects With β-Cell Dysfunction Have an Accentuated Incretin Release
Garduño‐García, J. D. J., Gastaldelli, A., DeFronzo, R. A., Lertwattanarak, R., Holst, J. J., & Musi, N. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00260 · Cited by 32
Self-citationMinor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men
Matikainen, N., Björnson, E., Söderlund, S., Borén, C., Eliasson, B., Pietiläinen, K. H., Bogl, L. H., Hakkarainen, A., Lundbom, N. M. I., Rivellese, A. A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0145890 · Cited by 23
“Defects in both secretion and insulinotropic actions of GLP-1 and GIP appear as early signs of insulin resistance characterizing the metabolic syndrome [7, 8].”
BackgroundSelf-citationIncretin and Glucagon Levels in Adult Offspring Exposed to Maternal Diabetes in Pregnancy
Kelstrup, L., Clausen, T. D., Mathiesen, E. R., Hansen, T. F., Holst, J. J., & Damm, P. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3978 · Cited by 26
Self-citationGlucagon and other proglucagon-derived peptides in the pathogenesis of obesity
Holst, J. J. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.964406 · Cited by 21
Self-citationMatikainen, N., Söderlund, S., Björnson, E., Bogl, L. H., Pietiläinen, K. H., Hakkarainen, A., Lundbom, N. M. I., Eliasson, B., Räsänen, S., Rivellese, A. A., et al. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.03.003 · Cited by 26
“Defects in either secretion or insulinotropic actions of GLP-1 and GIP are early signs of acquired insulin resistance characterizing the metabolic syndrome [5,16].”
BackgroundResultSelf-citationPhilosophical determinants of obesity as a disease
Kilov, D., & Kilov, G. (2017) · Obesity Reviews · doi:10.1111/obr.12597 · Cited by 24
“In addition, secretion of glucagon-like peptide-1 (GLP-1), an important satiety hormone (18), is attenuated in obesity, with higher GLP-1 responses associated with a lesser degree of obesity (19).”
BackgroundNagahisa, T., Yamaguchi, S., Kosugi, S., Homma, K., Miyashita, K., Irie, J., Yoshino, J., & Itoh, H. (2022) · Endocrinology · doi:10.1210/endocr/bqac023 · Cited by 20
GLP-1-related proteins attenuate the effects of mitochondrial membrane damage in pancreatic β cells
Ogata, M., Iwasaki, N., Ide, R., Takizawa, M., & Uchigata, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.03.143 · Cited by 17
“In the glucose tolerance test, obese individuals without liver fat and who retained insulin sensitivity, did not show alterations in GLP-1 secretion, whereas obese subjects with liver fat showed reduction in GLP-1 secretion compared to the prevailing glucose concentration in the test [12].”
BackgroundPAGE, L. C., & Freemark, M. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00409-7 · Cited by 19
Smith, K., Taylor, G., Allerton, D. M., Brunsgaard, L. H., Davies, K. A. B., Stevenson, E., & West, D. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.696977 · Cited by 18
“In the present study, we confirm previous reports that GLP-1 secretion is disordered in obese individuals (27, 28), particularly in those with abdominal adiposity (52).”
ResultNagahisa, T., Kosugi, S., & Yamaguchi, S. (2023) · Nutrients · doi:10.3390/nu15061494 · Cited by 15
Hibi, M., Hari, S., Yamaguchi, T. F., Mitsui, Y., Kondo, S., & Katashima, M. (2019) · Nutrients · doi:10.3390/nu11092126 · Cited by 18
Stinson, S. E., Alzola, I. F. D. R., Hovendal, E. D. B., Lund, M. A. V., Fonvig, C. E., Holm, L. A., Jonsson, A. E., Frithioff‐Bøjsøe, C., Christiansen, M., Pedersen, O. B., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad728 · Cited by 13
“Young adults with obesity, higher liver fat content, and hepatic insulin resistance show a similar attenuated GLP-1 response to oral glucose compared with healthy controls (39).”
BackgroundSelf-citationPerakakis, N., Kokkinos, A. D., Angelidi, A. M., Tsilingiris, D., Gavrieli, A., Yannakoulia, M., Tentolouris, N., & Mantzoros, C. S. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.07.001 · Cited by 13
Johnson, M. L., Saffrey, M. J., & Taylor, V. (2017) · Peptides · doi:10.1016/j.peptides.2017.02.010 · Cited by 12
The Gut: A Key to the Pathogenesis of Type 2 Diabetes?
Holst, J. J., Pedersen, J., Wewer Albrechtsen, N. J., & Knop, F. K. (2017) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2017.0015 · Cited by 11
“11,12 Probably it is of greater importance that the insulinotropic action of both hormones is also impaired.”
Self-citationHunt, J. E., Holst, J. J., & Jepsen, S. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.884501 · Cited by 12
“98170-4), and (125)I-labeled human GIP(1-42) tracer (cat.”
MethodSelf-citationFerjan, S., Jensterle, M., Oblak, T., Žitnik, I. P., Marc, J., Goričar, K., Dolžan, V., & Janež, A. (2019) · Journal of International Medical Research · doi:10.1177/0300060519865351 · Cited by 12
“Some of the mechanisms behind the different GLP-1 responses in our cohort may include genetic variation in the regulation of GLP-1 synthesis, which has also been observed in some other studies.(10,35,39,40) Twin studies have shown that the GLP-1 response has a heritability of up to 67%.”
BackgroundResultInfluentialTang, M., Zhao, L., Huang, F., Wang, T., Wu, X., Chen, S., Fu, J., Jiang, C., Wei, S., Zeng, X., et al. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1495695 · Cited by 8
“For the liver, GLP-1 has been found to inhibit the deposition of liver fat (90), and further research has confirmed that its antagonists may be beneficial for the treatment of NAFLD (91).”
Rodriguez, N. S., & Hartmann, P. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100058 · Cited by 13
Larsson, M., Patrone, C., von Euler, M., Holst, J. J., & Nathanson, D. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0896-z · Cited by 7
Self-citationCardiometabolic effects of antidiabetic drugs in non‐alcoholic fatty liver disease
Rix, I., Pedersen, J. S., Storgaard, H., & Gluud, L. L. (2018) · Clinical Physiology and Functional Imaging · doi:10.1111/cpf.12526 · Cited by 8
Virtuoso, A., Forkman, B., Sarruf, D. A., Tveden‐Nyborg, P., & Sørensen, D. B. (2017) · Applied Animal Behaviour Science · doi:10.1016/j.applanim.2017.10.012 · Cited by 6
Gerstenberg, M. K., Andersen, D. B., Torz, L., Castorena, C. M., Bookout, A. L., Hartmann, B., Rehfeld, J. F., Petersen, N., Holst, J. J., & Kuhre, R. E. (2023) · Acta Physiologica · doi:10.1111/apha.13947 · Cited by 5
Self-citationGut Peptide Alterations in Type 2 Diabetes and Obesity: A Narrative Review
Tzeravini, E., Simati, S., Anastasiou, I. A., Dalamaga, Μ., & Kokkinos, A. D. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00687-7 · Cited by 8
“Conversely, other studies have reported no difference [ 87, 89, 98, 126– 128] in GIP levels in individuals with obesity compared to lean ones.”
InfluentialSridhar, A., Khan, D., Flatt, P. R., Moffett, R. C., & Irwin, N. (2023) · Peptides · doi:10.1016/j.peptides.2023.171093 · Cited by 6
Babenko, A. Y., Matveev, G. A., Алексеенко, Т. И., Derevitskii, I. V., Kokina, M. A., & Shlyakhto, E. V. (2020) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2019-25-6-639-652 · Cited by 6
Eriksen, R., White, M. C., Dawed, A. Y., García‐Pérez, I., Posma, J. M., Haid, M., Sharma, S., Prehn, C. P., Thomas, E. L., Koivula, R. W., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae119 · Cited by 3
“…that in the context of acquired obesity, lower incremental GLP-1 secretion is associated with higher adiposity and decreased insulin sensitivity (31), and the ADDITION-PRO study showing that in people with predia-betes a higher incremental GLP-1 was associated with lower adiposity (BMI and…”
BackgroundSelf-citationClinical markers associated with glycaemic response to dipeptidyl peptidase‐4 inhibitor therapy
Yamagishi, S. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3024 · Cited by 2
“The observations that GLP‐1 response was blunted in insulin‐resistant patients with fatty liver or in individuals with fasting hypertriglycaeridemia could support their speculation.(6,7)”
BackgroundGhrelin and glucagon-like peptide-1 according to body adiposity and glucose homeostasis
Lopes, K. G., da Silva, V. L., Lopes, F. D. A. M., Bouskela, E., de Souza, M. D. G. C., & Kraemer‐Aguiar, L. G. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000611 · Cited by 4
“Meal-induced GLP-1 upregulation was reduced with increasing BMI (41-43), especially in the presence of liver steatosis (44).”
BackgroundBæch‐Laursen, C., Ucin, J. V., Galsgaard, K. D., Llana, J., Kissow, H., Rehfeld, J. F., Holst, J. J., Pedersen, B. K., & Sanchís, P. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106152 · Cited by 3
Self-citationUse of a Nebulizer to Deliver High Frequency High Flow with a Nasal Cannula
Goldstein, M. (2017) · Academic Journal of Pediatrics & Neonatology · doi:10.19080/ajpn.2017.02.555619
Secretion and Impact of Gut Hormones in Obesity and Diabetes
Holst, J. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00264-9
Self-citationPhysical activity promotes gut adaptation, responses to nutrients, and sensitivity to gut peptidesPreprint
Bæch‐Laursen, C., Ucin, J. V., Galsgaard, K. D., Llana, J., Kissow, H., Holst, J. J., Pedersen, B. K., & Sanchís, P. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.12.653520
Self-citationLow Weight Loss Response to Incretin Analogs: A Systematic Review
Gaskin, P. S., & Chami, P. (2026) · Obesity Reviews · doi:10.1111/obr.70145 · Cited by 1
“Matikainen et al. 2014 found that GLP-1 responses are heritable and blunted in acquired obesity with high liver fat and insulin resistance [38].”
Azlan, A. H. M., Subramaniyan, V., Ong, L. C., Dawe, G. S., & Ravi, R. N. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100741
Metadata
- Authors
- Matikainen, N., Bogl, L. H., Hakkarainen, A., Lundbom, J., Lundbom, N., Kaprio, J., Rissanen, A., Holst, J. J., & Pietiläinen, K. H.
- Affiliations
- University of Helsinki (FI)
- University of Copenhagen (DK)
- Corresponding author
- Pietiläinen, Kirsi H.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-12-11
- Volume
- 37
- Issue
- 1
- Pages
- 242-251
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2141742385
- Cited by
- 63
- References
- 38
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 2 · 2020: 3 · 2019: 8 · 2018: 7 · 2017: 7 · 2016: 3 · 2015: 4 · 2014: 4 · 2013: 2
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Funders
- Novo Nordisk Fonden (#NNF10OC1013354)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- glucagon-like peptide-1, incretin response, heritability, hepatic lipid accumulation, insulin resistance, glucose-dependent insulinotropic polypeptide, peptide YY, monozygotic twins, dizygotic twins, discordant twins, oral glucose tolerance test, type 2 diabetes risk
- MeSH terms
- Adult, Blood Glucose, Body Weight, Female, Gastric Inhibitory Polypeptide, Glucose Tolerance Test, Humans, Insulin, Insulin Resistance, Liver, Male, Obesity, Peptide Fragments, Lipid Metabolism, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.